Optic Atrophy Following Prophylactic Chemotherapy and Cranial Radiation for Acute Lymphocytic Leukemia

Fishman, Martin L.; Bean, S. Charles; Cogan, David G.

doi:10.1016/0002-9394(76)90544-4

Cited by 78 publications

(13 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent with this notion, blindness and deafness have been documented after industrial exposure to cobalt [25] . Similar symptoms were observed in patients receiving 60 cobalt radiotherapy for acute lymphocytic leukemia [26] , and cobalt chloride for treatment of anemia [27] . In addition, in vitro studies have demonstrated that cobalt induces cell toxicity and death [28] .…”

Section: Systemic Effectssupporting

confidence: 68%

Metal release from hip prostheses: cobalt and chromium toxicity and the role of the clinical laboratory

Campbell

Estey

2012

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Individuals with advanced hip disease suffer from pain, impaired hip function, and decreased quality of life. Roughly one million metal-on-metal (MoM) hip prostheses have been implanted worldwide in order to ameliorate these issues. While most MoM hip replacements are successful, some patients suffer from serious adverse effects secondary to the release of metal debris due to implant wear and corrosion. MoM hip prostheses are comprised predominantly of cobalt and chromium, and the serum concentration of these metal ions has been shown to correlate with both implant wear and the accumulation of metal debris in the periprosthetic tissue. Consequently, measurement of cobalt and chromium concentrations may be useful in the assessment of implant function and the potential for adverse effects in the follow-up of patients with MoM hip prostheses. The purpose of this Mini Review is to describe the adverse biological consequences of metal release from hip prostheses, provide an overview of the clinical utility of cobalt and chromium measurement and the current recommendations for testing, and alert laboratorians and physicians to the many challenges associated with measuring these metal ions.

show abstract

Section: Systemic Effectssupporting

confidence: 68%

Metal release from hip prostheses: cobalt and chromium toxicity and the role of the clinical laboratory

Campbell

Estey

2012

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

show abstract

“…The major observed toxicities include periorbital oedema, ocular pain, blurred vision, photophobia, conjunctivitis, blepharitis and decreased reflex tear secretion (10), possibly the result of the drug’s antimiotic effect in the rapidly dividing cells of the cornea and conjunctival epithelium (16). Intrathecal methotrexate can produce optic neuropathy and internuclear opthalmoplegia, which can be potentiated by concurrent cranial irradiation (30, 31). A severe case of meningeal metastasis of breast carcinoma that was treated with an intraventricular combination of methotrexate with cytosine arabinoside developed multiple foci of axonal degeneration and demyelination in the optic nerve and the chiasm (32).…”

Section: Visual‐related Toxicity Of Treatment Agentsmentioning

confidence: 99%

Effects on the visual system might contribute to some of the cognitive deficits of cancer chemotherapy-induced ‘chemo-fog’

Raffa

Tallarida

2010

Journal of Clinical Pharmacy and Therapeutics

View full text Add to dashboard Cite

SUMMARY The diminution in certain aspects of cognitive function that is reported to occur in some patients during or after adjuvant cancer chemotherapy is variously known as ‘chemo-fog’, ‘chemo-brain’ or other such term. In addition to reported deficits in attention, concentration and other functions, most, if not all, of the studies report deficits involving visual-spatial function or visual memory. Since the visual system is part of the nervous system, it seems reasonable to ask if it is susceptible to some of the deleterious effects produced by adjuvant chemotherapeutic drugs. We propose here the possibility that some portion of the vision-related aspects of the ‘chemo-fog’ spectrum of cognitive deficits results from a direct action of the adjuvant drugs on the visual system or from drug / drug or site / site interaction between effects on the visual system and other critical brain regions.

show abstract

“…Radiation is thought to increase blood-brain barrier permeability so that more methotrexate enters the CNS [ 295 , 296 ]. Therefore, the toxic effects of these chemotherapeutic drugs can potentiate the adverse effects of radiation and vice versa [ 297 ]. Preexisting medical disorders, such as diabetes; and endocrinologic disturbances from Cushing's syndrome, and growth hormone-producing tumors, are additional risk factors [ 298 ].…”

Section: Radiation-induced Optic Neuropathymentioning

confidence: 99%

Nutritional and Toxic Optic Neuropathies

Wang

Sadun

Chan

2014

Optic Nerve Disorders

View full text Add to dashboard Cite

Optic Atrophy Following Prophylactic Chemotherapy and Cranial Radiation for Acute Lymphocytic Leukemia

Cited by 78 publications

References 21 publications

Metal release from hip prostheses: cobalt and chromium toxicity and the role of the clinical laboratory

Metal release from hip prostheses: cobalt and chromium toxicity and the role of the clinical laboratory

Effects on the visual system might contribute to some of the cognitive deficits of cancer chemotherapy-induced ‘chemo-fog’

Nutritional and Toxic Optic Neuropathies

Contact Info

Product

Resources

About